Spero Therapeutics to Report Second Quarter 2026 Financial Results and Provide Business Update on August 12, 2026
Spero Therapeutics, a clinical-stage biopharmaceutical company focusing on immunology and inflammation, will report its Q2 2026 financial results after market close on August 12, followed by a conference call to discuss the results and provide updates on its business and pipeline, including its lead program SP001 targeting IgG4-related disease.